Specifically, Ditropan XL patients experienced 19.5 fewer weekly episodes of urge incontinence or wetting accidents. Dry mouth, the most commonly reported side effect with medications used to treat overactive bladder, was experienced by 28 percent of patients treated with Ditropan XL, versus 33 percent of patients treated with tolterodine. All other adverse events experienced by patients in both treatment groups occurred at low rates and with similar frequency. Detrol for a period of 12 weeks. To enhance the integrity of the study design, neither physicians nor patients could determine which product was being administered.
Overactive bladder can have a profound impact on patients and disrupt daily routines and activities.
Some patients may become socially isolated or even housebound because they fear the embarrassment of having urinary accidents in public. Ditropan XL should not be used by patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, and in patients who are at risk for these conditions, or those who have demonstrated hypersensitivity to the same substance or other components of the product. Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.